ADMA
ADMA Biologics, Inc.
Price Chart
Latest Quote
$7.97
-0.01 (-0.13%)
Current Price
| Previous Close | $7.98 |
| Open | $8.07 |
| Day High | $8.15 |
| Day Low | $7.89 |
| Volume | 2,349,489 |
Stock Information
| Shares Outstanding | 231.77M |
| Total Debt | $97.67B |
| Cash Equivalents | $55.92B |
| Revenue | $509.86M |
| Net Income | $165.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.85B |
| P/E Ratio | 11.72 |
| EPS (TTM) | $0.68 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $43.59B |
| Sales | $509.86M |
| Income | $165.35M |
| Book/sh | $1.68 |
| Cash/sh | $241.28 |
| Employees | 640 |
Financial Ratios
| Quick Ratio | 3.73 |
| Current Ratio | 6.95 |
| Debt/Eq | 110.67 |
Returns & Margins
| ROA | 21.99% |
| ROE | 43.30% |
| Gross Margin | 61.27% |
| Operating Margin | -123.39% |
| Profit Margin | 32.43% |
Ownership
| Insider Ownership | 1.87% |
| Institutional Ownership | 93.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 7.54 |
| P/S | 3.62 |
| P/B | 4.74 |
Analyst Data
| Recommendation | none |
| Target Price | $16.75 |
Technical Indicators
| SMA20 | $8.16 |
| SMA50 | $9.31 |
| SMA200 | $14.72 |
| RSI | 42.11 |
| ATR | 0.2896 |
| Shares Float | 226.73M |
| Short Float | 10.55% |
| Short Ratio | 2.62 |
| Volatility | 0.73 |
| Rel Volume | 0.57 |
Performance History
| Week | -0.13% |
| Month | -20.93% |
| Quarter | -48.21% |
| 6 Months | -59.58% |
| YTD | -55.43% |
| Year | -60.80% |
| 3 Years | +95.82% |
| 5 Years | +355.43% |
| 10 Years | +7.27% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $7.97 | 2,349,489 |
| 2026-06-04 | $7.98 | 2,203,200 |
| 2026-06-03 | $7.76 | 2,920,400 |
| 2026-06-02 | $7.60 | 3,279,800 |
| 2026-06-01 | $7.90 | 3,548,900 |
| 2026-05-29 | $7.98 | 3,100,100 |
| 2026-05-28 | $7.93 | 2,764,400 |
| 2026-05-27 | $7.92 | 3,545,900 |
| 2026-05-26 | $8.15 | 3,357,700 |
| 2026-05-22 | $8.24 | 2,973,300 |
| 2026-05-21 | $8.46 | 3,345,300 |
| 2026-05-20 | $8.56 | 4,542,000 |
| 2026-05-19 | $8.63 | 3,076,100 |
| 2026-05-18 | $8.38 | 3,351,500 |
| 2026-05-15 | $8.27 | 3,718,900 |
| 2026-05-14 | $8.50 | 3,317,700 |
| 2026-05-13 | $8.50 | 4,267,700 |
| 2026-05-12 | $8.41 | 8,219,500 |
| 2026-05-11 | $7.88 | 8,592,900 |
| 2026-05-08 | $8.17 | 10,208,400 |
| 2026-05-07 | $8.47 | 29,724,000 |
| 2026-05-06 | $10.08 | 12,973,200 |
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
đ° Latest News
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-06-05T15:30:18Z
US High Growth Tech Stocks with Promising Potential
Simply Wall St. âĸ 2026-06-05T11:38:28Z
New Strong Sell Stocks for June 3rd
Zacks âĸ 2026-06-03T10:54:00Z
ADMA Biologics (ADMA) Valuation After 2026 Guidance Reset And BIVIGAM Headwinds
Simply Wall St. âĸ 2026-06-01T20:08:43Z
ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV
Insider Monkey âĸ 2026-06-01T11:37:19Z
Is ADMA Biologics, Inc. (ADMA) Among the Best Russell 2000 Stocks to Invest In According to Hedge Funds?
Insider Monkey âĸ 2026-06-01T08:03:41Z
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
Zacks âĸ 2026-05-27T18:32:00Z
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
Zacks âĸ 2026-05-26T18:58:00Z
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Motley Fool âĸ 2026-05-21T21:51:11Z
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
Motley Fool âĸ 2026-05-21T21:39:19Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $209,456,000 | $199,244,000 | $161,665,000 | $112,417,000 |
| Cost Of Revenue | $217,408,000 | $206,901,000 | $169,273,000 | $118,815,000 |
| Total Revenue | $510,173,000 | $426,454,000 | $258,215,000 | $154,080,000 |
| Operating Revenue | $510,173,000 | $426,454,000 | $258,215,000 | $154,080,000 |
| Expenses | ||||
| Interest Expense | $7,110,000 | $13,930,000 | $25,027,000 | $19,279,000 |
| Total Expenses | $318,730,000 | $287,471,000 | $236,583,000 | $193,445,000 |
| Other Income Expense | $-3,548,000 | $-1,436,000 | $-26,461,000 | $-7,305,000 |
| Other Non Operating Income Expenses | $-212,000 | $-193,000 | $-287,000 | $-635,000 |
| Net Non Operating Interest Income Expense | $-5,239,000 | $-11,833,000 | $-23,410,000 | $-19,234,000 |
| Interest Expense Non Operating | $7,110,000 | $13,930,000 | $25,027,000 | $19,279,000 |
| Operating Expense | $101,322,000 | $80,570,000 | $67,310,000 | $74,630,000 |
| Other Operating Expenses | $4,836,000 | $4,245,000 | $4,266,000 | $17,843,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Net Interest Income | $-5,239,000 | $-11,833,000 | $-23,410,000 | $-19,234,000 |
| Interest Income | $1,871,000 | $2,097,000 | $1,617,000 | $45,000 |
| Normalized Income | $149,612,144 | $198,654,970 | $-2,065,000 | $-59,234,000 |
| Net Income From Continuing And Discontinued Operation | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Total Operating Income As Reported | $191,443,000 | $138,983,000 | $21,632,000 | $-39,365,000 |
| Net Income Common Stockholders | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Net Income | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Net Income Including Noncontrolling Interests | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Net Income Continuous Operations | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Pretax Income | $182,656,000 | $125,714,000 | $-28,239,000 | $-65,904,000 |
| Special Income Charges | $-3,336,000 | $-1,243,000 | $-26,174,000 | $-6,670,000 |
| Interest Income Non Operating | $1,871,000 | $2,097,000 | $1,617,000 | $45,000 |
| Operating Income | $191,443,000 | $138,983,000 | $21,632,000 | $-39,365,000 |
| Depreciation Amortization Depletion Income Statement | $144,000 | $388,000 | $724,000 | $715,000 |
| Depreciation And Amortization In Income Statement | $144,000 | $388,000 | $724,000 | $715,000 |
| Amortization Of Intangibles Income Statement | $144,000 | $388,000 | $724,000 | $715,000 |
| Gross Profit | $292,765,000 | $219,553,000 | $88,942,000 | $35,265,000 |
| Per Share | ||||
| Diluted EPS | - | $0.81 | $-0.13 | $-0.33 |
| Basic EPS | - | $0.85 | $-0.13 | $-0.33 |
| Other | ||||
| Tax Effect Of Unusual Items | $-653,856 | $-261,030 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $201,198,000 | $148,932,000 | $31,294,000 | $-32,842,000 |
| Total Unusual Items | $-3,336,000 | $-1,243,000 | $-26,174,000 | $-6,670,000 |
| Total Unusual Items Excluding Goodwill | $-3,336,000 | $-1,243,000 | $-26,174,000 | $-6,670,000 |
| Reconciled Depreciation | $8,096,000 | $8,045,000 | $8,332,000 | $7,113,000 |
| EBITDA (Bullshit earnings) | $197,862,000 | $147,689,000 | $5,120,000 | $-39,512,000 |
| EBIT | $189,766,000 | $139,644,000 | $-3,212,000 | $-46,625,000 |
| Diluted NI Availto Com Stockholders | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Tax Provision | $35,726,000 | $-71,959,000 | $0 | $0 |
| Other Special Charges | $3,336,000 | $1,243,000 | $26,174,000 | $6,670,000 |
| Amortization | $144,000 | $388,000 | $724,000 | $715,000 |
| Research And Development | $4,762,000 | $1,813,000 | $3,300,000 | $3,614,000 |
| Selling General And Administration | $91,580,000 | $74,124,000 | $59,020,000 | $52,458,000 |
| Diluted Average Shares | - | $243,342,466 | $223,977,315 | $197,874,895 |
| Basic Average Shares | - | $233,084,236 | $223,977,315 | $197,874,895 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $473,158,000 | $345,028,000 | $131,177,000 | $147,431,000 |
| Total Assets | $624,242,000 | $488,678,000 | $329,182,000 | $348,461,000 |
| Total Non Current Assets | $157,730,000 | $157,268,000 | $72,169,000 | $78,059,000 |
| Other Non Current Assets | $8,600,000 | $5,657,000 | $4,670,000 | $4,770,000 |
| Non Current Deferred Assets | $73,261,000 | $84,280,000 | $0 | - |
| Non Current Deferred Taxes Assets | $73,261,000 | $84,280,000 | $0 | - |
| Goodwill And Other Intangible Assets | $4,162,000 | $3,990,000 | $4,029,000 | $4,543,000 |
| Other Intangible Assets | $632,000 | $460,000 | $499,000 | $1,013,000 |
| Current Assets | $466,512,000 | $331,410,000 | $257,013,000 | $270,402,000 |
| Other Current Assets | $7,458,000 | $8,029,000 | $5,334,000 | $5,095,000 |
| Assets Held For Sale Current | $6,530,000 | $0 | - | - |
| Inventory | $206,465,000 | $170,235,000 | $172,906,000 | $163,280,000 |
| Receivables | $158,429,000 | $49,999,000 | $27,421,000 | $15,505,000 |
| Accounts Receivable | $158,429,000 | $49,999,000 | $27,421,000 | $15,505,000 |
| Allowance For Doubtful Accounts Receivable | $-300,000 | $-200,000 | $-100,000 | $-100,000 |
| Gross Accounts Receivable | $158,729,000 | $50,199,000 | $27,521,000 | $15,605,000 |
| Cash Cash Equivalents And Short Term Investments | $87,630,000 | $103,147,000 | $51,352,000 | $86,522,000 |
| Cash And Cash Equivalents | $87,630,000 | $103,147,000 | $51,352,000 | $86,522,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $79,885,000 | $82,116,000 | $141,418,000 | $154,442,000 |
| Long Term Debt And Capital Lease Obligation | $75,976,000 | $80,898,000 | $140,373,000 | $153,537,000 |
| Long Term Debt | $69,330,000 | $72,337,000 | $130,594,000 | $142,833,000 |
| Current Debt And Capital Lease Obligation | $3,909,000 | $1,218,000 | $1,045,000 | $905,000 |
| Current Debt | $2,813,000 | - | - | - |
| Other Current Borrowings | $2,813,000 | - | - | - |
| Net Debt | - | - | $79,242,000 | $56,311,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $146,922,000 | $139,660,000 | $193,976,000 | $196,487,000 |
| Total Non Current Liabilities Net Minority Interest | $77,381,000 | $84,118,000 | $144,170,000 | $157,220,000 |
| Non Current Deferred Liabilities | $1,405,000 | $1,547,000 | $1,690,000 | $1,833,000 |
| Current Liabilities | $69,541,000 | $55,542,000 | $49,806,000 | $39,267,000 |
| Other Current Liabilities | $6,815,000 | $1,996,000 | $2,365,000 | $1,796,000 |
| Payables And Accrued Expenses | $58,817,000 | $52,328,000 | $46,214,000 | $36,423,000 |
| Interest Payable | $172,000 | $2,857,000 | $546,000 | - |
| Payables | $31,135,000 | $23,700,000 | $15,660,000 | $13,229,000 |
| Total Tax Payable | $8,616,000 | $3,481,000 | $0 | - |
| Income Tax Payable | $8,616,000 | $3,481,000 | $0 | - |
| Accounts Payable | $22,519,000 | $20,219,000 | $15,660,000 | $13,229,000 |
| Other Non Current Liabilities | - | $1,673,000 | $2,107,000 | $1,850,000 |
| Current Deferred Liabilities | - | $143,000 | $182,000 | $143,000 |
| Equity | ||||
| Common Stock Equity | $477,320,000 | $349,018,000 | $135,206,000 | $151,974,000 |
| Total Equity Gross Minority Interest | $477,320,000 | $349,018,000 | $135,206,000 | $151,974,000 |
| Stockholders Equity | $477,320,000 | $349,018,000 | $135,206,000 | $151,974,000 |
| Retained Earnings | $-161,653,000 | $-308,583,000 | $-506,256,000 | $-478,017,000 |
| Other | ||||
| Treasury Shares Number | $1,919,070 | - | - | - |
| Ordinary Shares Number | $237,874,496 | $236,620,545 | $226,063,032 | $221,816,930 |
| Share Issued | $239,793,566 | $236,620,545 | $226,063,032 | $221,816,930 |
| Tangible Book Value | $473,158,000 | $345,028,000 | $131,177,000 | $147,431,000 |
| Invested Capital | $549,463,000 | $421,355,000 | $265,800,000 | $294,807,000 |
| Working Capital | $396,971,000 | $275,868,000 | $207,207,000 | $231,135,000 |
| Capital Lease Obligations | $7,742,000 | $9,779,000 | $10,824,000 | $11,609,000 |
| Total Capitalization | $546,650,000 | $421,355,000 | $265,800,000 | $294,807,000 |
| Treasury Stock | $32,090,000 | $0 | - | - |
| Additional Paid In Capital | $671,039,000 | $657,577,000 | $641,439,000 | $629,969,000 |
| Capital Stock | $24,000 | $24,000 | $23,000 | $22,000 |
| Common Stock | $24,000 | $24,000 | $23,000 | $22,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,405,000 | $1,547,000 | $1,690,000 | $1,833,000 |
| Long Term Capital Lease Obligation | $6,646,000 | $8,561,000 | $9,779,000 | $10,704,000 |
| Current Capital Lease Obligation | $1,096,000 | $1,218,000 | $1,045,000 | $905,000 |
| Current Accrued Expenses | $27,682,000 | $28,628,000 | $30,554,000 | $23,194,000 |
| Goodwill | $3,530,000 | $3,530,000 | $3,530,000 | $3,530,000 |
| Net PPE | $71,707,000 | $63,341,000 | $63,470,000 | $68,746,000 |
| Accumulated Depreciation | $-38,348,000 | $-33,552,000 | $-26,737,000 | $-19,477,000 |
| Gross PPE | $110,055,000 | $96,893,000 | $90,207,000 | $88,223,000 |
| Leases | $14,983,000 | $21,066,000 | $20,811,000 | $17,931,000 |
| Construction In Progress | $8,457,000 | $8,149,000 | $2,273,000 | $6,727,000 |
| Other Properties | $34,769,000 | $29,939,000 | $30,728,000 | $29,253,000 |
| Machinery Furniture Equipment | $11,921,000 | $11,612,000 | $11,838,000 | $10,429,000 |
| Buildings And Improvements | $26,886,000 | $21,788,000 | $20,218,000 | $19,544,000 |
| Land And Improvements | $13,039,000 | $4,339,000 | $4,339,000 | $4,339,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $52,055,000 | $48,121,000 | $70,286,000 | $58,465,000 |
| Work In Process | $57,798,000 | $61,641,000 | $49,621,000 | $56,171,000 |
| Raw Materials | $96,612,000 | $60,473,000 | $52,999,000 | $48,644,000 |
| Current Deferred Revenue | - | $143,000 | $182,000 | $143,000 |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $27,505,000 | $110,097,000 | $3,819,000 | $-73,419,000 |
| Operating Activities | ||||
| Operating Cash Flow | $50,396,000 | $118,672,000 | $8,800,000 | $-59,508,000 |
| Cash Flow From Continuing Operating Activities | $50,396,000 | $118,672,000 | $8,800,000 | $-59,508,000 |
| Operating Gains Losses | $3,345,000 | $1,349,000 | $26,356,000 | $7,097,000 |
| Investing Activities | ||||
| Capital Expenditure | $-22,891,000 | $-8,575,000 | $-4,981,000 | $-13,911,000 |
| Investing Cash Flow | $-21,891,000 | $-8,575,000 | $-4,981,000 | $-13,911,000 |
| Cash Flow From Continuing Investing Activities | $-21,891,000 | $-8,575,000 | $-4,981,000 | $-13,911,000 |
| Net Other Investing Changes | $1,000,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-31,940,000 | - | - | - |
| Financing Cash Flow | $-44,022,000 | $-58,302,000 | $-38,989,000 | $108,852,000 |
| Cash Flow From Continuing Financing Activities | $-44,022,000 | $-58,302,000 | $-38,989,000 | $108,852,000 |
| Net Other Financing Charges | $-14,128,000 | $-5,796,000 | $-16,492,000 | $-7,682,000 |
| Net Common Stock Issuance | $-31,940,000 | $0 | $0 | $64,645,000 |
| Issuance Of Capital Stock | - | $0 | $0 | $64,645,000 |
| Common Stock Issuance | - | $0 | $0 | $64,645,000 |
| Other | ||||
| Repayment Of Debt | $-105,938,000 | $-60,000,000 | $-158,601,000 | $-100,036,000 |
| Issuance Of Debt | $105,000,000 | $0 | $135,000,000 | $151,750,000 |
| Interest Paid Supplemental Data | $9,078,000 | $10,668,000 | $18,051,000 | $13,880,000 |
| Income Tax Paid Supplemental Data | $19,683,000 | $9,392,000 | $0 | $0 |
| End Cash Position | $87,630,000 | $103,147,000 | $51,352,000 | $86,522,000 |
| Beginning Cash Position | $103,147,000 | $51,352,000 | $86,522,000 | $51,089,000 |
| Changes In Cash | $-15,517,000 | $51,795,000 | $-35,170,000 | $35,433,000 |
| Proceeds From Stock Option Exercised | $2,984,000 | $7,494,000 | $1,104,000 | $175,000 |
| Common Stock Payments | $-31,940,000 | - | - | - |
| Net Issuance Payments Of Debt | $-938,000 | $-60,000,000 | $-23,601,000 | $51,714,000 |
| Net Long Term Debt Issuance | $-938,000 | $-60,000,000 | $-23,601,000 | $51,714,000 |
| Long Term Debt Payments | $-105,938,000 | $-60,000,000 | $-158,601,000 | $-100,036,000 |
| Long Term Debt Issuance | $105,000,000 | $0 | $135,000,000 | $151,750,000 |
| Net Intangibles Purchase And Sale | $-316,000 | $-349,000 | $-210,000 | $0 |
| Purchase Of Intangibles | $-316,000 | $-349,000 | $-210,000 | $0 |
| Net PPE Purchase And Sale | $-22,575,000 | $-8,226,000 | $-4,771,000 | $-13,911,000 |
| Purchase Of PPE | $-22,575,000 | $-8,226,000 | $-4,771,000 | $-13,911,000 |
| Change In Working Capital | $-139,595,000 | $-18,539,000 | $-10,123,000 | $-18,286,000 |
| Change In Other Current Liabilities | $-1,231,000 | $-1,144,000 | $-791,000 | $-502,000 |
| Change In Payables And Accrued Expense | $7,542,000 | $5,192,000 | $11,369,000 | $8,334,000 |
| Change In Accrued Expense | $5,212,000 | $1,042,000 | $7,530,000 | $7,534,000 |
| Change In Payable | $2,330,000 | $4,150,000 | $3,839,000 | $800,000 |
| Change In Account Payable | $2,330,000 | $4,150,000 | $3,839,000 | $800,000 |
| Change In Prepaid Assets | $-1,246,000 | $-2,680,000 | $841,000 | $-634,000 |
| Change In Inventory | $-36,230,000 | $2,671,000 | $-9,626,000 | $-38,556,000 |
| Change In Receivables | $-108,430,000 | $-22,578,000 | $-11,916,000 | $13,072,000 |
| Changes In Account Receivables | $-108,430,000 | $-22,578,000 | $-11,916,000 | $13,072,000 |
| Other Non Cash Items | $574,000 | $808,000 | $6,287,000 | $5,257,000 |
| Stock Based Compensation | $20,026,000 | $13,616,000 | $6,187,000 | $5,215,000 |
| Deferred Tax | $11,020,000 | $-84,280,000 | $0 | $0 |
| Deferred Income Tax | $11,020,000 | $-84,280,000 | $0 | $0 |
| Depreciation Amortization Depletion | $8,096,000 | $8,045,000 | $8,332,000 | $7,113,000 |
| Depreciation And Amortization | $8,096,000 | $8,045,000 | $8,332,000 | $7,113,000 |
| Gain Loss On Sale Of PPE | $9,000 | $106,000 | $182,000 | $427,000 |
| Net Income From Continuing Operations | $146,930,000 | $197,673,000 | $-28,239,000 | $-65,904,000 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-05-30